Thrombocytopenia is a common perioperative clinical problem. While global haemostasis is influenced by many patientand procedure-related factors, the contribution of thrombocytopenia to bleeding risk is difficult to predict, as platelet count does not linearly correlate with likelihood of bleeding. Thus, the widely used definition of thrombocytopenia and grading of its severity have limited clinical utility. We present a summary and analysis of the current recommendations for invasive procedures in thrombocytopenic patients, although the platelet count at which any given procedure may safely proceed is unknown. The benefits and risks of preoperative platelet transfusions should be assessed on a patientby-patient basis, and alternatives to platelet transfusion should be considered. In non-emergent surgeries or in postoperative thrombocytopenic patients, haematology consultation should be considered to guide diagnostics and management. We present a pragmatic approach to the evaluation of perioperative thrombocytopenia.
Thrombocytopenia is typically defined as a platelet count below 150Â10 9 L À1 and is common in the perioperative setting, occurring in approximately 5e10% of patients. 1, 2 While haemostatic function depends on multiple factors, platelet number and function are key elements. In this review, we address the role of platelet count and platelet function in the perioperative care of patients undergoing non-cardiac surgery or procedures and offer an approach to the clinical management of the thrombocytopenic surgical patient. The safety of regional anaesthesia in patients with abnormal haemostasis is an extensive topic that falls outside the scope of this review. This article is intended to serve as a pragmatic review for use in daily clinical practice. The manuscript is structured in a way that may help a practicing clinician in charge of a patient with thrombocytopenia to quickly find the most important information relating to the current recommendations and underlying evidence. We did not carry out a systematic literature review. A systematic review would decrease the probability of excluding relevant publications, but would also result in a larger and more detailed manuscript that could be difficult to use as a quick clinical reference.
Platelet count and clinical outcomes
A normal platelet count is within the range of 150e450Â10 9 
L
À1 , subject to inter-laboratory variation. 3 Without physiologic or pathophysiologic perturbations, the baseline platelet count is relatively stable over the lifetime of an individual. 4 Thus, a substantial change in platelet count is suggestive of an alteration in normal physiology, such as pregnancy or an underlying pathological process. Data from a large observational study in asymptomatic nonhospitalised surgical patients without indications for coagulation testing suggest that there may be a relationship between preoperative thrombocytopenia and 30-day mortality. 1 In a multivariable analysis, a platelet count of 101e150Â10 9 L À1 was associated with a 30% higher likelihood of death [adjusted odds ratio 1.31; 95% confidence interval (CI) 1.11e1.56, P 0.01], and a platelet count of 100Â10 9 L À1 nearly doubled the likelihood of death (adjusted odds ratio 1.93; 95% CI 1.43e2.61, P 0.001). Furthermore, patients with a platelet count of 100Â10 9 L
À1
were more likely to develop sepsis, renal complications, and adverse pulmonary outcomes, though the authors did not report on the relationship between platelet count and bleeding. The multiple adverse outcomes in thrombocytopenic patients may not simply be related to the role of platelets in haemostasis. A normal platelet count is 15e40 times higher than is necessary to achieve haemostasis. 5 While this may be a reflection of the functional reserve commonly observed with biological systems, it could suggest that other functions of platelets require higher platelet counts. 6 Indeed, platelets are involved not only in haemostasis, but also in inflammatory and immune responses and wound healing. 7 In pathologic states, platelets may promote excess inflammation and be associated with organ damage, such as acute kidney injury and acute lung injury. 8 The recent finding that more than half of the body's normal platelet production occurs in the lungs may offer some additional support for these arguments. 9 Thrombocytopenia and the risk of bleeding Thrombocytopenia has been subcategorised for surgical purposes into mild (100e149Â10 9 L À1 ), moderate (50e99Â10 9 L À1 ),
and severe (<50Â10 9 L À1 ). 10 The clinical utility of such subcategorisation is limited as the relationship between platelet count and bleeding risk is not linear and depends on platelet function and other patient-specific variables (Fig. 1) .
Data from large studies suggest that the risk of spontaneous bleeding is difficult to predict until platelet count decreases to extremely low values, below approximately 10Â10 9 L
.
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Because high-quality data quantifying the bleeding risk in thrombocytopenic surgical patients does not exist, we explored data from other medical populations. Most studies assessing the risk of spontaneous bleeding by platelet count were performed in patients with haematologic malignancies, in whom anaemia, chemotherapy, and radiation may further modify the risk of bleeding. In these patients, platelet counts above 10Â10 9 L À1 are sufficient to allow for normal thrombin generation 12 and therefore prevent spontaneous bleeding. This is supported by data demonstrating that platelet transfusion to a threshold higher than 10Â10 9 L À1 , the threshold for prophylactic transfusion recommended by AABB (formerly, American Association of Blood Banks) guidelines, does not affect the incidence of spontaneous bleeding ( Fig. 1 ).
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In patients with platelet counts of 10Â10 9 L
À1
, the rate of spontaneous bleeding is high, but the rate of clinically-relevant major bleeding is not. In a recent study of more than 1200 cancer patients with platelet counts of 10Â10 9 L À1 or lower for at least 5 days, 70% experienced at least one episode of bleeding classified as WHO Grade 2 or higher, but only 2% had Grade 4 bleeding and only one died of hemorrhage. 15 The WHO bleeding scale broadly classifies bleeding into Grade 0 (no bleeding), Grade 1 (minimal bleeding, such as petechiae), Grade 2 (mild blood loss, such as visible blood in stool or urine), Grade 3 (gross blood loss, such as profuse GI bleeding or minor intracerebral haemorrhage), and Grade 4 (debilitating, life-threatening bleeding). Compared with patients with a platelet count of !81Â10 9 L
, patients with a platelet count of 5Â10 9 L À1 had a higher risk of bleeding (odds ratio 3.1; 95% CI 2.0e4.8). In this study, no distinct pattern of decreasing bleeding risk with increasing platelet count was seen in the range from 6 to 80Â10 9 L
. In addition to platelet count, many other factors affect the likelihood of bleeding. For example the risk of bleeding varies with age; in a study of 117 patients with immune thrombocytopenia (ITP), the risk of major bleeding was almost 30 times higher in patients older than 60 yr in comparison with patients younger than 40 yr. 16 The risk of bleeding also depends on the aetiology of thrombocytopenia: ITP patients bleed less commonly than do other patients at similarly low platelet counts, probably because of the increased size and function of their platelets. Perioperative administration of fluids, blood products, and medications may further attenuate the haemostatic effectiveness of a given platelet count.
Thrombocytopenia and procedures
There is extremely limited data to inform perioperative management of patients with thrombocytopenia. Figure 1 summarises acceptable platelet counts and indications for platelet transfusions in thrombocytopenic patients undergoing invasive procedures. Most such 'threshold' recommendations are based on low quality evidence, expert opinion, or practice review. 17e19 Nearly all studies examining prophylactic platelet transfusions in preoperative thrombocytopenic patients are retrospective and observational. Nonetheless, we have attempted to review those studies that might be of clinical utility in the perioperative management of patients with thrombocytopenia.
A large systematic review of 17 randomised controlled trials and 55 observational studies examined the role of prophylactic platelet transfusions in thrombocytopenic patients, finding reduced rates of clinically significant bleeding, but no mortality benefit, in patients with haematologic malignancies receiving prophylactic platelet transfusions for a platelet threshold of 10 or 20Â10 9 L
À1
. 20 In a subset of patients undergoing central venous catheter placement, bleeding rates were similar for those receiving prophylactic platelet transfusion and those who did not, although all patients with platelet counts below 50Â10 9 L À1 received platelet transfusion. 20 
Noncardiac surgery
In a single-centre retrospective cohort study of 13 978 noncardiac surgical patients, 860 patients had a platelet count of 100Â10 9 L À1 and 71 received platelet transfusion before operation (none received platelets during surgery). 21 Preoperative platelet transfusion did not improve patient outcomes or decrease perioperative red blood cell (RBC) requirements. Patients receiving preoperative platelet transfusion were more likely to have higher ASA physical status, lower baseline haemoglobin concentrations and platelet counts, higher rates of postoperative ICU admission, and a longer hospital stay. Additionally, they were more likely to receive red cell transfusion. 21 In one study of 246 patients with end-stage liver disease, platelet count was not associated with higher blood product transfusion requirements. 22 It is worth noting that certain guidelines relating to liver instrumentation in cirrhotic patients suggest specific platelet thresholds 17 (such as UK guidelines recommending >50Â10 9 L À1 for a liver biopsy); the findings from this study do not support such recommendations. In a subset of surgical patients, thrombocytopenia may be a component of a pathophysiologic cascade associated with the underlying disease. In such patients, the severity of thrombocytopenia may reflect the severity of the disease. For example, in patients with solid tumours of the liver 23 and brain, 24 preoperative thrombocytopenia was associated with postoperative mortality. In recipients of liver transplants, the degree of thrombocytopenia after surgery, a probable marker of intraoperative pathophysiologic perturbations, was also associated with surgical complications, graft dysfunction, and sepsis. 25 
Interventional radiology procedures
A large single-centre retrospective study examined the utility of prophylactic platelet transfusions in patients undergoing interventional radiology procedures. 26 In . In a sensitivity analysis in patients with platelet counts 50Â10 9 L
À1
, prophylactic platelet transfusions did not reduce the frequency of RBC transfusion. Of note, patients who were transfused in this study were more likely to have a haematologic malignancy, lower baseline platelet count, increased incidence of emergency procedures, and a higher rate of general anaesthesia.
Acute abdominal complications in thrombocytopenic patients with haematological malignancies
Acute abdominal complications are common in patients with malignancies, particularly after chemotherapy. 27 Surgical problems that are more likely in cancer patients include haemorrhage, peritonitis, cholecystitis, intestinal obstruction, appendicitis, and splenic infarction. 28 A retrospective review of 58 haematologic malignancy patients undergoing emergency abdominal surgery concluded that intraoperative thrombocytopenia was not associated with prognosis; the frequency of surgical bleeding was not reported. 27 
Thrombocytopenia and the airway
It is likely that severe thrombocytopenia increases the risk of bleeding with airway manipulation, though supporting evidence is lacking. In one study of 166 patients with median duration of thrombocytopenia ( 30Â10 9 L À1 ) of 18 days, there was only one non-epistaxis bleeding episode involving the airway, a 'throat and mouth haemorrhage'. 29 Limited data is available on the safety of flexible bronchoscopy in thrombocytopenic patients. In a retrospective study of 150 thrombocytopenic patients who underwent bronchoscopy, only one patient had bleeding that required continuous suctioning; it resolved spontaneously. 30 Subgroup analysis of 35 patients (platelet count 30Â10 9 L À1 ) demonstrated no episodes of clinically significant bleeding. Some of the patients received prophylactic platelet transfusions, but in many of these patients, platelet counts did not increase beyond 50Â10 9 L
À1
. In another retrospective study of 37 mechanically-ventilated ICU patients with a mean platelet count 27Â10 9 L À1 , 12 patients had tracheobronchial bleeding that did not require RBC transfusion. 31 In a prospective study of 66 flexible bronchoscopies in 47 patients with a median platelet count of 37Â10 9 L À1 undergoing haematopoietic stem cell transplantation, five patients had bleeding complications. 32 Severe epistaxis occurred in one patient with a platelet count of 14Â10 9 L
, minimal epistaxis was documented in three other patients with platelet counts between 14 and 55Â10 9 L À1 , and a patient with a platelet count of 120Â10 9 L À1 developed haemoptysis. Each study concluded that flexible bronchoscopy is safe in most patients with thrombocytopenia.
In line with the existing data, the British Thoracic Society Guidelines suggest that bronchoscopy with lavage can be safely performed at platelet counts >20Â10 9 L À1 .
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Qualitative platelet dysfunction and procedures
Acquired platelet dysfunction
Acquired qualitative platelet defects secondary to uraemia, cardiopulmonary bypass, and medications are common in surgical patients. Typical offending medications include aspirin, the non-aspirin NSAIDs, P2Y 12 adenosine diphosphate receptor antagonists (ticlopidine, clopidogrel, prasugrel, ticagrelor, and cangrelor), dipyridamole, and glycoprotein IIb/IIIa antagonists (abciximab, eptifibatide, and tirofiban). Selective serotonin reuptake inhibitors are thought to reduce platelet function, but the clinical impact is less clear. Antiplatelet agents are routinely held before operative management whenever possible in the elective surgical setting, but patients often require emergency surgery in the setting of bleeding provoked or exacerbated by an antiplatelet medication. More recently, a randomised trial to evaluate the effect of platelet transfusions for patients who had suffered acute spontaneous primary intracerebral haemorrhage while on antiplatelet agents found that platelet transfusion was inferior to standard of care; there were more serious adverse events (e.g. enlargement of intracerebral haemorrhage or infections) in the patients who received platelet transfusions (42% compared with 29% receiving standard care). 34 Importantly, patients in this trial did not undergo invasive neurosurgical management of the haemorrhage. This study concluded that platelet transfusion may be deleterious for this patient population, challenging the long-accepted notion that patients on aspirin presenting with cerebral haemorrhage benefit from platelet transfusion. 34 Patients who require ophthalmology procedures while on antiplatelet agents are a noteworthy subgroup in clinical practice. A comprehensive guide to perioperative management of such patients has been published previously. 35 The treatment of uremic platelet dysfunction is discussed below in the section discussing alternatives to platelet transfusion.
Inherited platelet disorders
Inherited platelet disorders may result in qualitative platelet dysfunction, varying degrees of thrombocytopenia, or both.
The clinical spectrum of bleeding is highly variable in this diverse group of disorders. A retrospective analysis of bleeding and transfusion with invasive procedures in a heterogenous group of 423 patients with inherited platelet disorders found excessive bleeding risk in those with Bernard-Soulier syndrome, autosomal variant Glanzmann thrombasthenia, and Hermansky-Pudlak syndrome. 36 Bleeding was twice as common in inherited platelet function disorders (24.8% of procedures) compared with inherited thrombocytopenias (13.4% of procedures). The latter were associated with infrequent surgical bleeding until the platelet count was below 68Â10 9 L À1 .
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Evaluation of thrombocytopenia in the perioperative patient
A complete evaluation of thrombocytopenia in any patient begins by obtaining a thorough haematologic history, including prior platelet count trends and analysis of any prior thrombocytopenic episodes. Also critical is an exacting medication history, including times of drug administration. In many cases, patients with mild thrombocytopenia of known aetiology may proceed to surgery without additional perioperative workup or haematology consultation. In cases of unclear aetiology, severe thrombocytopenia, or unexpected bleeding, haematology consultation is warranted to guide further diagnosis and treatment. The following discussion focuses on the causes of unexplained thrombocytopenia in the postoperative patient, in whom a normal platelet count was documented before surgery and in whom no known prior thrombocytopenic diagnosis exists.
Artifactual thrombocytopenia
The first step in the diagnostic workup of the thrombocytopenic postoperative patient is assessment for artifactual thrombocytopenia ('pseudothrombocytopenia'). The complete blood count is drawn in a tube containing the anticoagulant ethylenediaminetetraacetic acid (EDTA). Approximately 0.1% of individuals have clinically insignificant antibodies that result in platelet clumping in the presence of EDTA (Fig. 2a) or platelet satellitism around leukocytes (Fig. 2b ) resulting in a falsely low platelet count. 37, 38 Because the clumping of pseudothrombocytopenia occurs usually only in the setting of EDTA, performing an automated platelet count from patient blood in a citrated or heparinised tube instead of an EDTA tube can confirm the diagnosis and allow for an accurate estimate of the true platelet count.
Non-artifactual thrombocytopenia in the postoperative patient
Having excluded artifactual causes, thrombocytopenia may then be classified according to its basic pathophysiologic process (i.e. decreased platelet production, increased platelet destruction, platelet sequestration or dilution, or some combination of these processes). If platelet transfusion has occurred, a post-transfusion platelet count should always be obtained within 30 min of the completion of the first transfusion episode to allow calculation of the corrected count increment (CCI). Failure of the CCI to increase by the expected magnitude can provide valuable diagnostic information, such as the presence of antiplatelet antibodies indicative of an acute immunologic destructive process or platelet alloimmunisation. 39 Certain aetiologies of thrombocytopenia are suggested by history alone. Administration of large quantities of i. v. fluids during operation may result in a dilutional thrombocytopenia, but with conservation of overall platelet mass and no significant clinical consequence; in this situation, proportional reductions in haemoglobin, haematocrit, and the white blood cell count are typically seen along with the platelet decrease. Massive red cell transfusion may have the same result. 40 Severe thrombocytopenia (often <10Â10 9 L À1 ) in the days after blood product (typically platelet) transfusion may herald post-transfusion purpura secondary to prior sensitisation to certain platelet glycoproteins (typically HPA-1a) foreign to the patient (either via prior transfusion or pregnancy). Infection or sepsis may lead to precipitous decreases in the platelet count over a short period of time, which may be because of disseminated intravascular coagulation (DIC) or to the secretion of neuraminidase by certain bacteria; neuraminidase then cleaves sialic acids from platelets and leads to rapid platelet destruction by the Ashwell-Morrel receptor in the liver. 41 Acute, decompensated DIC is not uncommon in critically ill patients. The diagnosis of DIC is made in the setting of oozing from an i. v. line or venepuncture sites, mucocutaneous and possibly deeper tissue bleeding, thrombocytopenia, hypofibrinogenemia, and elevated prothrombin and partial thromboplastin times. D-dimer measurement is elevated in these patients, although this test may be of little utility in the postoperative patient who would be expected to have an elevated D-dimer at baseline. Additionally, thrombocytopenia may be attributable to the medications (vide infra) administered to treat infection and it is oftentimes impossible to discern whether thrombocytopenia is as a result of infection or to the antibiotics. Figure 3 illustrates an approach to thrombocytopenia in the postoperative patient. Of note, bone marrow examination is not mentioned in this algorithm; it is not a routine part of this evaluation and is reserved for rare circumstances in which acute bone marrow failure is a major consideration, such as drug-induced aplastic anaemia. While an in-depth discussion of each major aetiology of postoperative thrombocytopenia is beyond the scope of this review, drug-induced thrombocytopenia and heparin-induced thrombocytopenia will be discussed in further detail owing to their considerable perioperative relevance and management challenges.
Drug-induced thrombocytopenia
Drugs may cause thrombocytopenia by a variety of different pathophysiologic mechanisms, including immune-mediated destruction (e.g. vancomycin), bone marrow suppression (e.g. linezolid), precipitation of thrombotic microangiopathy (e.g. cyclosporine), and induction of platelet activation (e.g. heparin). The most common drugs resulting in thrombocytopenia in the postoperative setting are heparin agents and antibiotics. For specific queries, an online database listing all relevant drug-induced thrombocytopenia publications for any given drug is available. 42 The drugs most relevant to the perioperative setting with the greatest evidence for association with thrombocytopenia after exposure include glycoprotein IIb/IIIa inhibitors, amiodarone, ampicillin, haloperidol, ibuprofen, naproxen, piperacillin, ranitidine, trimethoprim-sulfamethoxazole, and vancomycin. 43 Each agent only rarely causes thrombocytopenia, so analysis of timing of drug initiation vs thrombocytopenia onset is critical to establish the link. For most drugs, the incidence of thrombocytopenia after exposure is not known and data associating the agent with thrombocytopenia are limited to published case reports and case series.
The severity of thrombocytopenia caused by any drug is highly variable. 44 If the patient's platelet count is high enough that postoperative bleeding is not a significant concern, the count can be monitored over the course of drug treatment assuming no concerns for a more serious aetiology (e.g. druginduced thrombotic microangiopathy). When the platelet count decreases to the point that bleeding is a concern, drug(s) considered to be the most likely offenders should be discontinued, if possible. The diagnosis may sometimes be confirmed clinically if the platelet count recovers after drug discontinuation. Most drugs result in thrombocytopenia via an immunemediated mechanism (although the rate of immune destruction, and therefore the nadir platelet count, varies widely); therefore, diagnostic testing in the form of an assay for drugdependent antiplatelet antibodies may be performed, but results typically are not known in time to guide urgent clinical decision-making. This laboratory confirmation may be especially helpful to determine the specific cause when multiple drugs are suspected. Importantly, a positive test is helpful in confirmation of the specific drug responsible, but negative testing does not exclude a drug as a cause of thrombocytopenia. 45 In cases in which the suspected drug is essential and required for an extended duration, platelet transfusion can be attempted, but may be ineffective in the setting of brisk immune-mediated platelet destruction. Unlike in primary ITP, corticosteroids have not demonstrated efficacy in druginduced ITP. 46 Therefore, an individualised approach to management is warranted. Intravenous immunoglobulin may work well, but if it is ineffective, use of a thrombopoietin (TPO) receptor agonist is a reasonable consideration. Although an off-label use for TPO receptor agonists, these agents are 
Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) occurs in up to 2.5% of inpatients receiving heparin and is most common in surgical patients (especially those subject to major trauma or major surgery). 49e51 HIT results from immunologic recognition of heparin-platelet factor 4 (PF4) complexes typically 5e10 days after heparin initiation, resulting in platelet activation, thrombocytopenia, and high thrombotic risk. 52, 53 Incidence of venous thromboembolism is 17e55%, incidence of arterial thrombosis is 3e10%, and mortality is 5e10% in patients with HIT. 49, 54 Asymptomatic HIT must be distinguished clinically from the modest platelet count decreases that may occur in the first several days after beginning heparin, a clinically insignificant entity known as heparin-associated thrombocytopenia (HAT). The distinction between these two entities is especially relevant to those patients undergoing cardiopulmonary bypass, in whom nearly half develop HAT, but only 1e2% develop HIT. 55 The first step in diagnosis is application of the 4Ts scoring system (Table 2) . 56 Patients with intermediate or higher
probability of HIT by the 4Ts score should undergo assessment for anti-heparin-PF4 antibodies [typically using an IgG-specific enzyme-linked immunosorbent assay (ELISA)], receive fourlimb Doppler ultrasonography to screen for occult venous thrombosis, 57 and heparin should be replaced with an alternative agent (typically the direct thrombin inhibitors argatroban or bivalirudin, although fondaparinux can be used offlabel). 49, 58 If ELISA testing is suggestive of HIT, a functional assay (serotonin release assay or heparin-induced platelet aggregation) assessing for platelet activation in the presence of heparin is confirmatory. 59 If confirmed, all heparincontaining products are to be avoided except under specific, time-limited, controlled clinical circumstances in which no other suitable options exist (such as cardiopulmonary bypass). After withdrawal of heparin, the platelet count will gradually normalise over the following 3e4 days; once !100Â10
L
À1 , i. v. direct thrombin inhibitor therapy should be transitioned to an oral anticoagulant or s. c. fondaparinux. 58 The greatest clinical experience is with warfarin, though a direct oral anticoagulant is reasonable. 57 The duration of the prothrombotic state in a patient with HIT is not entirely clear. For those without thrombosis, guidelines suggest anticoagulation should continue for a minimum of 4 weeks. 49 
Platelet function testing
Platelet function assessment is performed to identify qualitative platelet defects (e.g. inherited platelet function disorders, assessment of pharmacologic antiplatelet agents). While thrombocytopenia is much more common in the perioperative setting than qualitative defects, a brief discussion of the most common platelet function testing follows, as it may be relevant in select cases. A platelet function test of historical interest is the bleeding time, largely abandoned because of poor reproducibility and poor sensitivity to non-severe platelet function defects. 60 A more modern screening test for qualitative platelet abnormalities is platelet function analyser (PFA) testing, a specific instrument that reports the length of time before a platelet plug forms to stop flow through an aperture coated with platelet agonists (closure time or CT). While convenient, PFA testing is sensitive to haematocrit and platelet count and insensitive to mild platelet defects, limiting its value both generally and in the perioperative setting.
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A more useful platelet function assay is light transmission platelet aggregometry. In this laboratory test, platelet-rich plasma is placed in cuvettes between a light source and photocell, with various platelet agonists (such as adenosine diphosphate, collagen, epinephrine, and arachidonic acid) added, resulting in platelet activation and aggregation. This increases light transmission through the cuvette over time which is read by the photomultiplier cell and captured as a tracing for each agonist. Platelet response to each agonist allows for diagnosis of specific platelet defects; for example, aggregation in response to arachidonic acid is diminished in patients on aspirin. While light transmission platelet aggregometry is considered the gold standard, its major limitation is its susceptibility to numerous pre-analytical variables that can impact test results (such as agitation of the tubes before testing, as in a hospital's pneumatic tube system). It cannot be performed accurately at platelet counts under 100Â10 9 L
À1
. Moreover, it is poorly standardised, has a long turnaround time, and requires numerous tubes of blood to be drawn. 61 Assessment of viscoelastic properties of blood in vitro (thromboelastography) may also provide useful information on platelet function. However, this technique evaluates the combined effects of many components of haemostasis. Thus, it is not a platelet function test in a strict sense and is outside of the scope of this review.
Alternatives to platelet transfusion in the thrombocytopenic surgical patient
While platelet transfusion is the only currently available therapy capable of achieving a rapid, generally predictable increase in platelet count, platelet transfusion has several risks. In addition to the relatively common complications of blood product transfusion (volume overload and febrile non- Table 2 4Ts score for diagnosis of heparin-induced thrombocytopenia. Scoring is as follows: 3 points, low probability of HIT; 4e5 points, intermediate probability of HIT; 6e8 points, high probability of HIT. 56 Plt, platelet haemolytic transfusion reactions), less common but important risks associated with platelet transfusion include transfusion-associated acute lung injury, allergic reactions, clinically-relevant immunomodulation, post-transfusion purpura, infectious risk, and alloimmunisation with subsequent ineffectiveness of platelet transfusion. Because platelets cannot be frozen, they have the highest risk of bacterial sepsis of any blood product. 62 The immunomodulatory effects of blood product transfusion are particularly salient in the surgical and critical care populations, for whom the transient immunosuppression has been demonstrated to increase infection risk 63 and even increase the risk of cancer relapse after oncologic surgery. 64 Given these risks and the relative scarcity of platelets as a resource, proper alternatives to platelet transfusion should always be considered in the thrombocytopenic surgical patient. Non-specific haemostatic agents such as desmopressin, the antifibrinolytic agents (epsilon aminocaproic acid and tranexamic acid), or procoagulant bypass agents [recombinant factor VIIa and activated prothrombin complex concentrates (aPCC)] are a consideration, and the TPO receptor agonists (romiplostim, eltrombopag, avatrombopag and lusutrombopag) can raise the platelet count pharmacologically. Raising the haematocrit may also improve haemostasis in the patient who is both thrombocytopenic and anaemic.
Desmopressin
Desmopressin (1-deamino-8-D-arginine vasopressin, brand name DDAVP) is a rapid-acting vasopressin analogue that acts principally by inducing the release of large von Willebrand factor multimers from Weibel-Palade bodies in the vascular endothelium. 65 Desmopressin can be given by i. v., s. c., or intranasal routes and is commonly used in patients with mild haemophilia A and milder forms of von Willebrand disease to minimise bleeding in the perioperative setting. Desmopressin is also commonly used to promote haemostasis in patients with uremic platelet dysfunction based on improvements demonstrated in platelet function testing, 66, 67 although there have been no large, randomised studies demonstrating the magnitude of this benefit. It is potentially attractive from a mechanistic perspective for use as a non-specific haemostatic agent in thrombocytopenic patients, as increased circulating von Willebrand factor could theoretically improve platelet adhesion to the endothelial surface. One small randomised trial of cirrhotic thrombocytopenic patients undergoing dental extraction demonstrated no difference between desmopressin and platelet transfusion in reducing bleeding events, but only one bleeding event occurred in the trial population, rendering a comparison of efficacy impossible. 68 Despite the lack of evidence, desmopressin can be considered a non-specific haemostatic agent in thrombocytopenic surgical patients who are uremic or refractory to platelet transfusions. This agent is welltolerated, with hyponatremia being the most common adverse effect. This necessitates plasma sodium monitoring in all patients and administration no more frequently than three times daily. 69 Tachyphylaxis develops rapidly after the initial dose as a result of depletion of von Willebrand factor from endothelial cells, 65 so desmopressin is ideal for a short duration of use.
Antifibrinolytic agents
The antifibrinolytic agents epsilon aminocaproic acid and tranexamic acid are synthetic analogues of the amino acid lysine Considerably less evidence is available in thrombocytopenic patients, however. Efficacy was shown in a small ITP cohort, 74 but results were equivocal in patients with bone marrow failure. 75 It is reasonable to consider a trial of antifibrinolytic therapy in a thrombocytopenic patient refractory to platelet transfusion or for whom platelet transfusion is not acceptable (i.e. a Jehovah's Witness).
Procoagulant bypass agents
The procoagulant bypass agent recombinant factor VIIa (rFVIIa, eptacog alfa) and activated prothrombin complex concentrates (aPCC) are widely used to achieve haemostasis in patients with haemophilia and factor inhibitors. The largest study utilising these agents in the thrombocytopenic setting was a randomised trial of 100 thrombocytopenic hematopoietic stem cell transplant patients with moderate or severe bleeding; rFVIIa administration was not effective in improving the patient's bleeding score, but did result in increased incidence of venous thromboembolism. 76 A Cochrane analysis of 29 randomised controlled trials of rFVIIa use for the prevention and treatment of bleeding outside of the haemophilia setting more generally (including studies of patients with and without thrombocytopenia) demonstrated decreased red cell transfusion requirements and decreased blood loss, but no evidence of mortality benefit and an increase in arterial thromboembolic events with the use of rFVIIa. 77 Given the lack of evidence demonstrating efficacy, the considerable financial cost, and the concern for promotion of thrombosis, rFVIIa and aPCC should not be considered as alternatives to platelet transfusion.
Thrombopoietin receptor agonists
The TPO receptor agonists romiplostim, eltrombopag, avatrombopag, and lusutrombopag act on bone marrow megakaryocytes and megakaryocyte progenitors to increase platelet production. Because of the normal kinetics of thrombopoiesis, the platelet count begins to increase approximately 5e7 days after administration of a TPO receptor agonist and peaks 10e14 days later (so none of these agents are capable of achieving a rapid platelet increase). Given these time constraints, use of these agents for the management of perioperative thrombocytopenia has been examined in multiple studies. A retrospective cohort study of 47 thrombocytopenic patients receiving romiplostim to increase platelet count for surgery (median baseline platelet count 47Â10 9 L À1 ) showed that romiplostim was highly efficacious for this purpose, with median platelet count on the day of surgery of 164Â10 9 L À1 and all but one patient undergoing surgery on the originally scheduled date. 78 Median time to platelet count !100Â10 9 L À1 was 13 days. Most patients in this cohort underwent major surgery (e.g. open cardiac surgery, total joint arthroplasty, abdominopelvic surgery, or neurological surgery).
Because thrombocytopenia of chronic liver disease is due in large part to TPO deficiency, use of TPO receptor agonists is an attractive prospect in this patient population. In a large, randomised, controlled trial of 292 patients with chronic liver disease and thrombocytopenia who required a minor elective invasive procedure, eltrombopag or placebo was administered for 14 days before a planned elective invasive procedure. Eltrombopag was effective in reducing platelet transfusions and bleeding, but the study was terminated early because of increased incidence of portal venous thrombosis in the eltrombopag arm. Similarly, more recent studies of novel nonpeptide TPO receptor agonists (lusutrombopag and avatrombopag) for perioperative thrombocytopenia in chronic liver disease patients have demonstrated similar efficacy outcomes without increased rates of portal vein thrombosis. 79, 80 Avatrombopag was approved by the US FDA in May 2018 for treatment of perioperative thrombocytopenia in patients with chronic liver disease, based on the results on two randomised controlled trials enrolling a total of 435 patients demonstrating increased platelet counts (approximately 30e50Â10 9 L À1 higher on average) treated with 5 days of avatrombopag vs placebo before minor invasive procedures. 80 There was no increase in thromboembolism in patients treated with avatrombopag. Subsequently, lusutrombopag was approved by the US FDA in July 2018 for treatment of perioperative thrombocytopenia in patients with chronic liver disease based on the results of two randomised controlled trials enrolling a total of 312 patients demonstrating similar improvements in platelet count after 7 days of preoperative lusutrombopag. 79 
Raising the haematocrit
Haemostasis is improved in renal failure patients by increasing the haematocrit through transfusion or erythropoietin treatment. 81e84 The proposed mechanism is that the higher RBC mass (which flows in the centre of the blood vessel) 'pushes' platelets closer to the endothelial cell wall, thereby increasing the haemostatic effect. No definitive studies have documented such an increased haemostatic effect in thrombocytopenic patients who are not uremic.
Conclusions
The bleeding risk in thrombocytopenic patients undergoing surgical procedures is difficult to predict, and at any given platelet count, congenital or acquired platelet dysfunction may render available platelets less effective. Thus, the platelet count at which a given procedure carries an acceptable risk of bleeding is unique in each patient. Recommendations for procedure-specific 'safe' platelet counts often lack a robust evidence base and may reflect anecdotal experiences of those performing the procedure. The true magnitude of benefit of prophylactic platelet transfusion remains unclear and the need for platelet transfusion should be assessed on a patientby-patient basis. In non-emergent surgeries or postoperative thrombocytopenic patients, haematology consultation may be helpful in diagnosing the aetiology of thrombocytopenia, selecting appropriate therapy, and determining the utility of platelet transfusion or its alternatives.
